CASE REPORT

Rosette-forming glioneuronal tumours: two case reports and a review of the literature

XIAO-DAN HUANG, MD, HAN-WEN ZHANG, MD, YU-NING FENG, MD, YI LEI, MD and FAN LIN, MD, PhD

Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People’s Hospital, Shenzhen, China

Address correspondence to: Fan Lin
E-mail: foxetfoxet@gmail.com

The authors Xiao-dan Huang and Han-wen Zhang contributed equally to the work.

Xiao-dan Huang and Han-wen Zhang have contributed equally to this study and should be considered as co-first authors.

ABSTRACT

Rosette-forming glioneuronal tumour (RGNT) is a rare central nervous system (CNS) neoplasm that typically arises in the fourth ventricle. It is even more uncommon to arise outside the midline. In this paper, we report two cases of RGNT: one located in the fourth ventricle (a typical site), and the other in the right cerebellar hemisphere (a rare site). Both cases were misdiagnosed on imaging, and the results were inconsistent with the pathological diagnosis. The aim of the article is to deepen medical practitioners’ understanding of RGNT by learning from these two cases, summarising cases located in the cerebellar hemispheres and systematically reviewing RGNT.

SUMMARY

Rosette-forming glioneuronal tumour (RGNT) is a very rare but benign tumour of the central nervous system (CNS), first proposed by Komori in 2002.1 Due to its connection with the fourth ventricle, it was named “rosette-forming glioneuronal tumour of the fourth ventricle” in 2007 based on the unique structure of neural and glial components.2 As RGNT arising outside the fourth ventricle has been successively reported, which was renamed “rosette-forming glioneuronal tumours” and classified as a mixed neuron-glial tumour of WHO Class I in the 2016 version of the CNS classification.3 Currently, its origin is unclear. It is generally believed by researchers that it originates from the pluripotential subependymal cells (the periventricular germinal matrix) near the midline.4 It usually occurs in the midline and typically in the fourth ventricle and the cerebellar vermis.5 Here, we report two cases of RGNTs, with one being a more typical example and one being a more rare example.

CLINICAL PRESENTATION

Case 1

The patient was a 27-year-old male. 8 months ago, he presented with intermittent posterior occipital distension and heaviness of no obvious cause. Later, the patient’s headache symptoms worsened. The rest of the examination showed no significant abnormalities. Brain CT suggested the presence of tumorous lesions of the fourth ventricle. MRI examination in our hospital (Figure 1) showed a solid cystic occupancy in the patient’s fourth ventricle with a size of approximately 26 × 19 × 33 mm. The lesion grew downward along the fourth ventricles. The brainstem was compressed, and the supratentorial ventricles were expanded. Overall, the lesion showed a mixed signal on T1 weighted imaging (T1WI); on T2 weighted imaging (T2WI), the lesion showed a hyperintense signal. There was no obvious diffusion limitation on diffusion-weighted imaging (DWI). An enhanced scan showed heterogeneous and obvious enhancement. Imaging indicated a diagnosis of ventricular meningioma.

The patient underwent fourth ventricle space-occupying lesion resection under general anaesthesia, and the operation progressed smoothly.

Pathological results and light microscopy (Figure 2): the tumour cells were homogeneously distributed and uniform in size, with round nuclei and partial perinuclear cytoplasmic vacuolization.
Immunohistochemical results revealed the following: GFAP(+), Ki67 approximately 1%(+), P53(+), S100(+), Olig-2(+), H3K27Me3(+), Syn(+), NeuN(-), CgA(-), Braf(-).

Fluorescence in situ hybridization (FISH) results: no co-deletion of 1p/19q in tumour cells; IDH1 and IDH2 were wild type; and MGMT methylation was negative. In addition, there was no BRAF-KIAA1549 gene fusion. The final pathological results indicated “RGNT” in the fourth ventricle.

Case 2
A 31-year-old male was found to have an occupying lesion in the right cerebellar hemisphere on physical examination. No abnormality was found on examination. MRI examination in our hospital (Figure 3) showed space-occupying lesions in the right cerebellar hemisphere. The lesion was mostly hypointense on T1 weighted images, T2 weighted images showed predominantly hyperintense signal. There was no obvious enhancement after contrast injection. It was misdiagnosed as astrocytoma on imaging.

The patient underwent right cerebellar space-occupying lesion resection under general anaesthesia, and the operation progressed smoothly.

Pathological results and light microscopy (Figure 4) showed that the tumour cells were visible.

Immunohistochemical results revealed the following: CD34(−), Olig-2(+), GFAP(+), IDH1(−), NeuN(−), Syn(+), NF(+), Ki67 index <1%(+), S100(+), P53 slightly(+), CgA(−), H3K27M(−), H3K27Me3(−). FISH results revealed codeletion of 1p/19q(−), and IDH1 and IDH2 were wild type. The pathological results were consistent with RGNT-like manifestations.

**DISCUSSION**

RGNT is a rare benign primary tumour of the nervous system. It is mostly found in young people with a mean age of 29.8 years.
is slightly more common in females than in males.\textsuperscript{5} It frequently arises near the midline, most commonly in the fourth ventricle and cerebellar vermis. It can also occur in the pineal region, third ventricle, optic chiasm and spinal cord.\textsuperscript{5,6} The clinical manifestations of RGNTs are associated with the location of the lesion.\textsuperscript{6,7} Symptoms include headache, cerebellar ataxia, visual disturbances, nausea, and vomiting as well as vertigo.\textsuperscript{6}

Of the two cases reported here, in Case 1, all information including site, clinical symptoms, imaging and pathological manifestations, was consistent with typical RGNT. In contrast, Case 2 occurred at an extremely rare site (cerebellar hemisphere), and all clinical data were unremarkable. Interestingly, in this patient, the imaging data were different from previous tumorigenic lesions, as we could see normal striation in the cerebellar hemisphere. Therefore, we searched the literature and found a total of only six reports on RGNT involving the cerebellar hemispheres and summarised them in a table\textsuperscript{8–13} (Table 1).

Including this case reported here, no obvious difference was seen in the male to female ratio among these seven reports. We found four patients (57.1%) who presented with headache. On MRI, all the lesions had low signal intensity on $T_1$WI and high signal intensity on $T_2$WI. Enhanced scans vary in performance. Ultimately, all seven patients were treated by surgery.

Influenced by the components of the tumour, RGNTs tend to appear as cystic and solid occupancies on imaging. The density of solid lesions on CT is lower than that of normal brain parenchyma. Calcifications are visible internally.\textsuperscript{14} On MRI, the solid component of the tumour appears to have a hypo- or isosignal intensity on $T_1$WI and high signal intensity on $T_2$WI. Because of the low malignancy of the tumour and the lack of dense cell distribution, DWI usually has no significant diffusion limitation.\textsuperscript{14} Enhanced scans may show a special feature called “the green bell pepper sign”.\textsuperscript{14} The mass shows ring-like enhancement, the mucus component in the centre shows low signal intensity, and the surrounding tumour cells show low or no enhancement. The imaging presentation of two cases was consistent with the above. Due to the loose distribution of tumour tissue, there was no enhancement in Case 2. Inside the tumour, we could even see the normal striation of the cerebellar hemisphere, which is quite rare. In addition, several cases of spontaneous disappearance of RGNT enhancement have been reported without intervention. They have occurred as a manifestation of degenerative and inflammatory changes within the tumour affecting the permeability of the blood–brain barrier.\textsuperscript{15}

The imaging of RGNTs lacks specificity, and pathological examination is the gold-standard for diagnosis. In histopathological studies, RGNTs exhibit a characteristic biphasic structure: neuronal and glial cells coexist in a mixture. As previously described for RGNTs, the nerve cells are consistent in size and uniformly arranged.

Table 1. Cases of rosette-forming glioneuronal tumor of the cerebellar hemisphere

| Author           | Publication date | Sex | Symptoms                        | Location                                | $T_1$WI | $T_2$WI | MRI enhanced scan | Treatment                          |
|------------------|------------------|-----|---------------------------------|-----------------------------------------|---------|---------|--------------------|------------------------------------|
| Preusser et al.  | 2003             | M   | Not obvious                     | Cerebellar vermis, fourth ventricle     | Low     | High    | Ring enhancement  | Resection                          |
| Luan et al.      | 2010             | F   | Headache                        | And right cerebellar hemisphere        | Low     | High    | Point enhancement | Gross resection                    |
| Matyja et al.    | 2010             | F   | Headache, nausea,               | Right cerebellar hemisphere            | Low     | High    | Ring enhancement  | Partial excision                   |
| García et al.    | 2014             | M   | Balance disorder                | Cerebellar vermis and part of the left side | Low     | High    | Ring enhancement  | Surgery radiotherapy and chemotherapy |
| Beuriat et al.   | 2015             | F   | Headache                        | Cerebellar hemisphere                  | Low     | High    | No enhancement    | Subtotal resection                 |
| Kwon et al.      | 2019             | M   | Headache, dizziness, and nausea | Spinal cord, cerebellar hemisphere and  | Low     | High    | Uneven enhancement| Gross resection                    |
They form a rosette or pseudorosette structure around the blood vessels, and the centre of the rosettes are eosinophilic neuropil cores. The neuropil cores display strong immunoreactivity for synaptophysin, and the cytoplasmic protrusions express neuron-specific enolase (NSE). The glial component is similar to pilocytic astrocytoma. Immunoreactivity of glial fibrillary acidic protein (GFAP) and S100 is shown in the glial component. A low Ki67 index and a typically negative P53 are consistent with the diagnosis of low-grade tumours in RGNT. IDH-1/2 mutations may also be present in genetic testing. In addition, Philipp Sievers et al. reported the possibility of FGFR1 and PIK3CA co-mutations also be present in genetic testing. In addition, Philipp Sievers et al. reported the possibility of FGFR1 and PIK3CA co-mutations.

**Differential diagnosis**

Based on the absence of specificity of clinical manifestations and radiographic features of RGNT, the diagnosis can typically be confirmed only by post-operative pathology. The primary differential diagnosis of RGNT is as follows:

1. Pilocytic astrocytoma (PA): prevalent in children, it is mostly a cystic tumour with wall nodules. It has a typical presentation to RGNT on a plain scan, but wall nodules, not the cyst wall, are significantly strengthened.
2. Dysembrioplastic neuroepithelial tumour (DNET): DNET frequently occurs in children and adolescents, most of whom have a long history of drug-refractory epilepsy. The most common site of onset is the temporal lobe, followed by the frontal lobe. The imaging is also similar to RGNT, and most of them do not have significant enhancement on enhanced scans. It is often associated with cortical dysplasia. Mainly, there is no typical rosette structure of DNET.
3. Ependymoma: this tumour originates from the intraventricular ventricular epithelium. It is frequently seen in children under 5 years of age, and the fourth ventricle is considered the most common site. The tumour is often seen as a necrotic cystic lesion, and MRI often shows mixed signals with moderate enhancement on enhanced scans. The tumour may grow along the ventricular canal towards the Luschka or Magendie foramen of the fourth ventricle, forming a “cast” structure of the ventricle.
4. Central neurocytoma is usually located near the Monro foramen in the lateral ventricle. The signal of the solid portion is equal to the brain tissue, and the cystic portion is uncommon. Calcification and flow-through are characteristic of this tumour.
5. Medulloblastoma: it is highly malignant and has a high incidence in the age group of 4 to 8 years. The tumour mostly occurs in the cerebellar vermis and easily protrudes into the fourth ventricle. It has a long T1 signal and long T2 signal on MRI. DWI shows significantly limited diffusion, and the enhanced scan often shows more homogenous enhancement, so it is easy to distinguish from RGNT.
6. Diffuse midline glioma: As the most specific type of molecular typing in the 2016 version of WHO CNS tumours, it is also prevalent at midline sites but has a high degree of malignancy (WHO IV). It is diagnosed based on H3K27M positivity. On imaging, it is generally challenging to distinguish RGNT from DNET. H3K27Me3 is antagonistic to H3K27M, and patients with positive H3K27Me3 generally have a relatively high prognosis. Both of our cases were positive for H3K27Me3, so theoretically, the prognosis for RGNT is generally better.

**Treatment**

The current treatment of choice for RGNTs is surgery. Presently, gross total resection (GTR) is mainly recommended, and subtotal resection (STR) is preferred as an alternative. Despite the slow progression and good prognosis of RGNT, cases of dissemination to the soft meninges, cerebrospinal fluid, and even malignancy have been gradually reported. RGNT progresses slowly and has a good prognosis. In cases of soft meningeal and cerebrospinal fluid dissemination or even malignancy, adjuvant treatment options such as concurrent chemoradiotherapy can usually be added.

In conclusion, RGNT is a rare benign tumour of the neurological system. In addition to the common sites in the midline region, such as the fourth ventricle and the cerebellar vermis, it can also occur in bilateral cerebellar hemispheres. Case 1 is a typical case. Case 2 has a rare location and radiographic manifestation, not only arising in the right cerebellar hemisphere but also exhibiting cerebellar striation within the tumour. We hope to improve the understanding of RGNT among medical professionals by discussing these two cases.

**LEARNING POINTS**

- RGNT is a rare type of brain tumour that can occur at sites other than the midline.
- On enhanced scans, RGNT may show a special feature called “the green bell pepper sign”.
- Theoretically, patients diagnosed with RGNT with positive H3K27Me3 generally have a relatively high prognosis.
- The greatest difference between RGNT and other CNS tumours is the unique rosette structure of the pathology.

**CONTRIBUTORS**

Hw-Z contributed to the conception of the study; Xd-H and YL contributed significantly to analysis and manuscript preparation; FL performed the data analyses and wrote the manuscript; Yn-F helped perform the analysis with constructive discussions.

**FUNDING**

This study is supported by a grant from Basic Plan Program of Shenzhen, China (No. JCYJ20180228163333734) and Clinical Research Project of Shenzhen Second People’s Hospital, China (No.201933357021).

**PATIENT CONSENT**

Written informed consent for the case to be published (incl. images, case history and data) were obtained from the patients for publication of this case report, including the accompanying images.
ETHICS APPROVAL
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All involved patients signed an informed consent form.

DISCLOSURE
Thanks to Ms. Siling Gu for her help in this research.

REFERENCES
1. Komori T, Scheithauer BW, Hirose T. Rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol 2002; 26: 582–91. doi: https://doi.org/10.1097/00000478-200205000-00004
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97–109. doi: https://doi.org/10.1007/s00401-007-0243-4
3. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system. Acta Neuropathol 2016; 131: 97–109. doi: https://doi.org/10.1007/s00401-016-1545-1
4. Muly S, Liu S, Lee R, Nicolaou S, Rojas R, Khosa F. MRI of intracranial intraventricular lesions. Clin Imaging 2018; 52: 226–39. doi: https://doi.org/10.1016/j.clinimag.2018.07.021
5. Anyanwu CT, Robinson TM, Huang JH. Rosette-forming glioneuronal tumor: an update. Clin Transl Oncol 2020; 22: 623–30. doi: https://doi.org/10.1007/s12094-019-02179-8
6. Wilson CP, Chakraborty AR, Pelargos PE, Shi HH, Milton CK, Sung S, et al. Rosette-forming glioneuronal tumor: an illustrative case and a systematic review. Neurooncol Adv 2020; 2: vdaa116. doi: https://doi.org/10.1093/noajnl/vdaa116
7. Yang C, Fang J, Li G, Li S, Ha T, Wang J, et al. Histopathological, molecular, clinical and radiological characterization of rosette-forming glioneuronal tumor in the central nervous system. Oncotarget 2017; 8: 109175–90. doi: https://doi.org/10.18632/oncotarget.22846
8. Preusser M, Dietrich W, Czech T, Prayer D, Budka H, Hainfellner JA. Rosette-Forming glioneuronal tumor of the fourth ventricle. Acta Neuropathol 2003; 106: 506–8. doi: https://doi.org/10.1007/s00401-003-0758-2
9. Luan S, Zhuang D, Sun L, Huang F-P. Rosette-Forming glioneuronal tumor (RGNT) of the fourth ventricle: case report and review of literature. Clin Neurol Neurosurg 2010; 112: 362–4. doi: https://doi.org/10.1016/j.clineuro.2010.01.006
10. Matyja E, Grajakowska W, Nauman P, Ozieblo A, Bonicki W. Rosette-forming glioneuronal tumor of the fourth ventricle with advanced microvascular proliferation–a case report. Neuropathology 2011; 31: 427–32. doi: https://doi.org/10.1111/j.1440-1789.2010.01168.x
11. Garcia Cabezas S, Serrano Blanch R, Sanchez-Sanchez R, Palacios Eito A. Rosette-Forming glioneuronal tumour (RGNT) of the fourth ventricle: a highly aggressive case. Brain Tumor Pathol 2015; 32: 124–30. doi: https://doi.org/10.1007/s10014-014-0195-z
12. Beuriat P-A, Taziedde-Espariat A, Pages M, Varlet P, Di Rocco F. Rosette-Forming glioneuronal tumor outside the fourth ventricle: a case-based update. Childs Nerv Syst 2016; 32: 65–8. doi: https://doi.org/10.1007/s00381-015-2922-0
13. Kwon SM, Kim JH, Byun J, Kim Y-H, Hong SH, Cho YH, et al. Malignant transformation of a rosette-forming glioneuronal tumor to glioblastoma. World Neurosurg 2019; 130: 271–5. doi: https://doi.org/10.1016/j.wneu.2019.06.042
14. Gao L, Han F, Jin Y, Xiong J, Lv Y, Yao Z, et al. Imaging features of rosette-forming glioneuronal tumours. Clin Radiol 2018; 73: 275–82. doi: https://doi.org/10.1016/j.crad.2017.10.011
15. Tanaka F, Matsukawa M, Kogue R, Umino M, Maeda M, Uchida K, et al. A case of a rosette-forming glioneuronal tumor arising from the pons with disappearance of contrast enhancement. Radiol Case Rep 2019; 14: 899–902. doi: https://doi.org/10.1016/j.radcr.2019.05.011
16. Sievers P, Appay R, Schrimpf D, Stichel D, Reuss DE, Wepers AK, et al. Rosette-Forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathol 2019; 138: 497–504. doi: https://doi.org/10.1007/s00401-019-02038-4